Advanced search
1 file | 504.57 KB Add to list

4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial

Valerie Fonteyne (UGent) , Camille Sarrazyn, Martijn Swimberghe (UGent) , Gert De Meerleer (UGent) , Elke Rammant (UGent) , Barbara Vanderstraeten (UGent) , Frank Vanpachtenbeke (UGent) , Nicolaas Lumen (UGent) , Karel Decaestecker (UGent) , Roos Colman (UGent) , et al.
Author
Organization
Keywords
INTENSITY-MODULATED RADIOTHERAPY, NON-INFERIORITY, TOXICITY, REGIMEN, RISK

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 504.57 KB

Citation

Please use this url to cite or link to this publication:

MLA
Fonteyne, Valerie, Camille Sarrazyn, Martijn Swimberghe, et al. “4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer : Interim Safety Analysis of a Randomized Phase 3 Trial.” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 100.4 (2018): 866–870. Print.
APA
Fonteyne, Valerie, Sarrazyn, C., Swimberghe, M., De Meerleer, G., Rammant, E., Vanderstraeten, B., Vanpachtenbeke, F., et al. (2018). 4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(4), 866–870.
Chicago author-date
Fonteyne, Valerie, Camille Sarrazyn, Martijn Swimberghe, Gert De Meerleer, Elke Rammant, Barbara Vanderstraeten, Frank Vanpachtenbeke, et al. 2018. “4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer : Interim Safety Analysis of a Randomized Phase 3 Trial.” International Journal of Radiation Oncology Biology Physics 100 (4): 866–870.
Chicago author-date (all authors)
Fonteyne, Valerie, Camille Sarrazyn, Martijn Swimberghe, Gert De Meerleer, Elke Rammant, Barbara Vanderstraeten, Frank Vanpachtenbeke, Nicolaas Lumen, Karel Decaestecker, Roos Colman, Geert Villeirs, and Piet Ost. 2018. “4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer : Interim Safety Analysis of a Randomized Phase 3 Trial.” International Journal of Radiation Oncology Biology Physics 100 (4): 866–870.
Vancouver
1.
Fonteyne V, Sarrazyn C, Swimberghe M, De Meerleer G, Rammant E, Vanderstraeten B, et al. 4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2018;100(4):866–70.
IEEE
[1]
V. Fonteyne et al., “4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial,” INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 100, no. 4, pp. 866–870, 2018.
@article{8558975,
  author       = {Fonteyne, Valerie and Sarrazyn, Camille and Swimberghe, Martijn and De Meerleer, Gert and Rammant, Elke and Vanderstraeten, Barbara and Vanpachtenbeke, Frank and Lumen, Nicolaas and Decaestecker, Karel and Colman, Roos and Villeirs, Geert and Ost, Piet},
  issn         = {0360-3016},
  journal      = {INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS},
  keywords     = {INTENSITY-MODULATED RADIOTHERAPY,NON-INFERIORITY,TOXICITY,REGIMEN,RISK},
  language     = {eng},
  number       = {4},
  pages        = {866--870},
  title        = {4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial},
  url          = {http://dx.doi.org/10.1016/j.ijrobp.2017.12.016},
  volume       = {100},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: